Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07325097

A Prospective, Single Arm Study to Assess the Safety and Tolerability of PVEK Corneal Implant for the Treatment of Corneal Edema

Led by Precise Bio · Updated on 2026-01-12

15

Participants Needed

3

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and tolerability of PVEK, a tissue-engineered corneal implant, for people with corneal swelling caused by Fuchs' endothelial dystrophy or pseudophakic bullous keratopathy who need endothelial keratoplasty. This Phase 1 study aims to identify possible side effects after the implant and how many participants can complete 6 months after surgery without needing another treatment due to implant intolerance or ineffectiveness. About 15 participants will be involved and followed for up to 12 months after surgery. Participants will undergo implantation of the PVEK corneal endothelial implant in a single surgery. The implant combines a human collagen scaffold and corneal endothelial cells and is delivered into the eye during endothelial keratoplasty using a sterile injector system. After surgery, participants will use prescribed eye drops and attend scheduled follow-up visits for up to 12 months to monitor eye health and implant performance. During the study, participants will complete initial screening including eye exams and health checks before implantation. Follow-up visits will include vision tests, eye pressure measurements, and eye scans to assess corneal thickness and endothelial cell density. Researchers will track the incidence of adverse events for 12 months, monitor eye pressure, and evaluate visual acuity and corneal health. The main outcomes focus on safety and implant tolerability during the first 6 months and continued monitoring up to one year.

CONDITIONS

Brief Title

PVEK Corneal Implant For Treatment of Corneal Edema

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Corneal edema requiring endothelial keratoplasty due to Fuchs' endothelial dystrophy and/or pseudophakic bullous keratopathy
  • Pseudophakic study eye
  • Best corrected visual acuity (BCVA) in the study eye between 6/379 (1.8 logMAR) and 6/12 (0.3 logMAR)
  • Central corneal thickness greater than 0.6 mm by OCT
Not Eligible

You will not qualify if you...

  • Phakic study eye
  • Study eye is a "single sight eye" or fellow eye does not meet vision requirements
  • Malpositioned intraocular lens (dislocation or subluxation) in the study eye
  • Prior ocular procedures other than uncomplicated cataract surgery with stable, centered posterior chamber IOL
  • Axial length below 21 mm or above 26 mm
  • Other significant corneal disease beyond mild dry eye or prior keratoplasty in the study eye
  • Visually significant corneal scarring or opacities not expected to improve with treatment
  • Active ocular or eyelid infection or inflammation; active or prior herpetic ocular infection; uveitis
  • Glaucoma or history/suspicion of elevated intraocular pressure; screening IOP above 23 mmHg in either eye
  • Synechiae or abnormal anterior segment conditions (e.g., aphakia, aniridia)
  • Corneal endothelial cell density above 1000 cells/mm² at screening or not reliably measurable
  • Uncontrolled systemic conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Single administration with follow-up to 12 months

Participants undergo implantation of the PVEK tissue-engineered corneal endothelial implant in a single administration.

Multiple visits over 12 months for monitoring and assessments

Trial Site Locations

Total: 3 locations

1

Ophthalmological Center After S.V.Malayan

Yerevan, Armenia, 0048

Not Yet Recruiting

2

Sharei Zedek Medical Center

Jerusalem, Jerusalem, Israel, abecassis

Not Yet Recruiting

3

Rambam Medical Center

Haifa, Israel, 3109602

Actively Recruiting

Loading map...

Research Team

A

Amos Eitan

L

Lior Rosenberg Belmaker

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

ASTRA: A Phase 3 Randomized, Double-Masked Study of AURN001 ...

Corneal Edema

Actively Recruiting

12 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here